Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: This assessment updates and expands on two previous technology assessments that evaluated implantable cardioverter defibrillators (ICDs) for arrhythmias and cardiac resynchronisation therapy (CRT) for heart failure (HF). Objectives: To assess the clinical effectiveness and cost-effectiveness of ICDs in addition to optimal pharmacological therapy (OPT) for people at increased risk of sudden cardiac death (SCD) as a result of ventricular arrhythmias despite receiving OPT; to assess CRT with or without a defibrillator (CRT-D or CRT-P) in addition to OPT for people with HF as a result of left ventricular systolic dysfunction (LVSD) and cardiac dyssynchrony despite receiving OPT; and to assess CRT-D in addition to OPT for people with both conditions. Data sources: Electronic resources including MEDLINE, EMBASE and The Cochrane Library were searched from inception to November 2012. Additional studies were sought from reference lists, clinical experts and manufacturers’ submissions to the National Institute for Health and Care Excellence. Review methods: Inclusion criteria were applied by two reviewers independently. Data extraction and quality assessment were undertaken by one reviewer and checked by a second. Data were synthesised through narrative review and meta-analyses. For the three populations above, randomised controlled trials (RCTs) comparing (1) ICD with standard therapy, (2) CRT-P or CRT-D with each other or with OPT and (3) CRT-D with OPT, CRT-P or ICD were eligible. Outcomes included mortality, adverse events and quality of life. A previously developed Markov model was adapted to estimate the cost-effectiveness of OPT, ICDs, CRT-P and CRT-D in the three populations by simulating disease progression calculated at 4-weekly cycles over a lifetime horizon. Results: A total of 4556 references were identified, of which 26 RCTs were included in the review: 13 compared ICD with medical therapy, four compared CRT-P/CRT-D with OPT and nine compared CRT-D with ICD. ICDs reduced all-cause mortality in people at increased risk of SCD, defined in trials as those with previous ventricular arrhythmias/cardiac arrest, myocardial infarction (MI) > 3 weeks previously, non-ischaemic cardiomyopathy (depending on data included) or ischaemic/non-ischaemic HF and left ventricular ejection fraction ≤ 35%. There was no benefit in people scheduled for coronary artery bypass graft. A reduction in SCD but not all-cause mortality was found in people with recent MI. Incremental cost-effectiveness ratios (ICERs) ranged from £14,231 per quality-adjusted life-year (QALY) to £29,756 per QALY for the scenarios modelled. CRT-P and CRT-D reduced mortality and HF hospitalisations, and improved other outcomes, in people with HF as a result of LVSD and cardiac dyssynchrony when compared with OPT. The rate of SCD was lower with CRT-D than with CRT-P but other outcomes were similar. CRT-P and CRT-D compared with OPT produced ICERs of £27,584 per QALY and £27,899 per QALY respectively. The ICER for CRT-D compared with CRT-P was £28,420 per QALY. In people with both conditions, CRT-D reduced the risk of all-cause mortality and HF hospitalisation, and improved other outcomes, compared with ICDs. Complications were more common with CRT-D. Initial management with OPT alone was most cost-effective (ICER £2824 per QALY compared with ICD) when health-related quality of life was kept constant over time. Costs and QALYs for CRT-D and CRT-P were similar. The ICER for CRT-D compared with ICD was £27,195 per QALY and that for CRT-D compared with OPT was £35,193 per QALY. Limitations: Limitations of the model include the structural assumptions made about disease progression and treatment provision, the extrapolation of trial survival estimates over time and the assumptions made around parameter values when evidence was not available for specific patient groups. Conclusions: In people at risk of SCD as a result of ventricular arrhythmias and in those with HF as a result of LVSD and cardiac dyssynchrony, the interventions modelled produced ICERs of < £30,000 per QALY gained. In people with both conditions, the ICER for CRT-D compared with ICD, but not CRT-D compared with OPT, was < £30,000 per QALY, and the costs and QALYs for CRT-D and CRT-P were similar. A RCT comparing CRT-D and CRT-P in people with HF as a result of LVSD and cardiac dyssynchrony is required, for both those with and those without an ICD indication. A RCT is also needed into the benefits of ICD in non-ischaemic cardiomyopathy in the absence of dyssynchrony. Study registration: This study is registered as PROSPERO number CRD42012002062. Funding: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Carson, P., DiCarlo, L., DeMets, D., White, B. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032423 · Cited by 5,812
Cardiac Resynchronization in Chronic Heart Failure
Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013168 · Cited by 4,648 · cited 5×
“Sudden cardiac death All trials reported SCDs, although there were uncertainties within the MIRACLE trial data.(121)”
BackgroundMethodInfluentialMoss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., Levine, J. H., Saksena, S., Waldo, A. L., Wilber, D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352601 · Cited by 4,165 · cited 4×
“Other non-device-specific adverse events were reported by four trials.(75,82,90,99) In the MADIT I(99) and SCD-HeFT(75) trials only syncope (5%) and hypothyroidism (6%) affected ≥ 5% of people in the comparator groups.”
BackgroundMethodInfluentialCardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
Moss, A. J., Hall, W. J., Cannom, D. S., Klein, H., Brown, M. W., Daubert, J. P., Estes, N. A. M., Foster, E., Greenberg, H., Higgins, S. L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906431 · Cited by 3,157 · cited 3×
“The number of participants randomised ranged from 31(138) to 1820.(130) The length of follow-up was 6 months in the CONTAK-CD,(126) MIRACE ICD,(136) MIRACLE ICD II,(137) Pinter and colleagues(139) and RethinQ(142) studies, 12 months in the Piccirillo and colleagues(139) and RHYTHM ICD(144) studies and an average of 2.”
BackgroundMethodA Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease
Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., & Hafley, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412503 · Cited by 2,489 · cited 1×
“001).(146) The overall mortality rate at 5 years was 24% among patients who received a defibrillator and 55% among those who did not.”
BackgroundCardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
Tang, A. S. L., Wells, G. A., Talajic, M., Arnold, M. O., Sheldon, R., Connolly, S., Hohnloser, S. H., Nichol, G., Birnie, D. H., Sapp, J. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009540 · Cited by 1,859 · cited 5×
“Source: RAFT trial.(140) ECONOMIC ANALYSIS”
BackgroundMethodInfluentialGuidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction
Hohnloser, S. H., Kuck, K. H., Dorian, P., Roberts, R. S., Hampton, J. R., Hatala, R., Fain, E., Gent, M., & Connolly, S. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041489 · Cited by 1,519
Goldberger, J. J., Cain, M. E., Hohnloser, S. H., Kadish, A. H., Knight, B. P., Lauer, M. S., Maron, B. J., Page, R. L., Passman, R. S., Siscovick, D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.189375 · Cited by 1,450
Defibrillator implantation early after myocardial infarction
Steinbeck, G., Andresen, D., Seidl, K., Brachmann, J., Hoffmann, E., Wojciechowski, D., Kornacewicz-Jach, Z., Sredniawa, B., Lupkovics, G., Hofgärtner, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901889 · Cited by 690 · cited 6×
“All-cause mortality All 13 trials comparing the use of ICDs with the use of AADs in people at increased risk of SCD from ventricular arrhythmias reported measures of all-cause mortality as their primary outcome measure.(69,71,75,81,82,84,89,90,95,97,99,101,105) Four trials(71,81,84,89) assessed the use of ICDs compare…”
BackgroundMethodResultInfluentialSchron, E. B., Exner, D. V., Yao, Q., Jenkins, L. S., Steinberg, J. S., Cook, J. R., Kutalek, S. P., Friedman, P. L., Bubien, R. S., Page, R. L., et al. (2002) · Circulation · doi:10.1161/hc0502.103330 · Cited by 624
Quality of life in the Canadian Implantable Defibrillator Study (CIDS)
Irvine, J., Dorian, P., Baker, B., O'Brien, B. J., Roberts, R., Gent, M., Newman, D., & Connolly, S. J. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124049 · Cited by 368
Quality of Life with Defibrillator Therapy or Amiodarone in Heart Failure
Mark, D. B., Anstrom, K. J., Sun, J. L., Clapp-Channing, N. E., Tsiatis, A. A., Davidson-Ray, L., Lee, K. L., & Bardy, G. H. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706719 · Cited by 260 · cited 1×
“The effects of ICD shocks on QoL were assessed in the SCD-HeFT trial using the SF-36 (see Table 26).(107) A comparison of the changes in scores for those who had received a shock within 1 month of a scheduled QoL assessment and those who had not received a shock showed a significant decrease in the QoL of those who re…”
MethodWilkoff, B. L., Auricchio, A., Brugada, J., Cowie, M., Ellenbogen, K. A., Gillis, A. M., Hayes, D. L., Howlett, J. G., Kautzner, J., Love, C. J., et al. (2008) · Europace · doi:10.1093/europace/eun122 · Cited by 231
Cited by
Defibrillator implantation in patients with nonischemic systolic heart failure
Køber, L., Thune, J. J., Nielsen, J. C., Haarbo, J., Videbæk, L., Korup, E., Jensen, G., Hildebrandt, P., Steffensen, F. H., Bruun, N. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608029 · Cited by 1,763
Understanding heart failure; explaining telehealth—a hermeneutic systematic review
Greenhalgh, T., A’Court, C., & Shaw, S. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0594-2 · Cited by 141
Moulaert, V. R. M., Goossens, M., Heijnders, I. L. C., Verbunt, J. A., & Heugten, C. M. V. (2016) · Resuscitation · doi:10.1016/j.resuscitation.2016.06.015 · Cited by 44
Metadata
- Authors
- Colquitt, J. L., Mendes, D., Clegg, A. J., Harris, P., Cooper, K., Picot, J., & Bryant, J.
- Venue
- Health Technology Assessment
- Published
- 2014-08
- Volume
- 18
- Issue
- 56
- Pages
- 1-560
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1993257960
- Cited by
- 74
- References
- 16
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.